Compass Therapeutics, Inc.
No SEC Form 4 filings for $CMPX in the last 30 days.
Compass Therapeutics, Inc. (CMPX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VE
Compass Therapeutics, Inc. (CMPX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001738021 0001738021 2026-06-10 2026-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
This article provides access to a DEFA14A filing by Compass Therapeutics. These filings are preliminary proxy statements that include important information for shareholders prior to a definitive proxy statement.
Over the past 7 days, alphai's AI scored 1 news story mentioning CMPX (Compass Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent CMPX coverage spans financial news, earnings and corporate actions.
Near-term catalyst is FDA feedback timing tied to a potential tovecimig BLA, alongside updated cash runway into 2028.
Routine corporate governance disclosure; unlikely to change near-term fundamentals, but can affect sentiment around board/executive oversight.
The DEFA14A filing indicates upcoming shareholder meetings and potential strategic decisions. Given the neutral sentiment score, immediate market impact is limited, but the information could influence long-term valuation.
Positive financial results and clinical progress suggest potential upside for CMPX in the medium to long term.
Compass Therapeutics (CMPX) has reached a new 52-week high, indicating strong upward momentum. The stock's bullish sentiment suggests potential for further gains in the near term, supported by strategic advancements and investor confidence.
alphai scores every news story that mentions CMPX with an AI model for sentiment and relevance, and aggregates insider trades from Compass Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Compass Therapeutics, Inc. (CMPX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VE
7 min readCompass Therapeutics, Inc. (CMPX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001738021 0001738021 2026-06-10 2026-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readThis article provides access to a DEFA14A filing by Compass Therapeutics. These filings are preliminary proxy statements that include important information for shareholders prior to a definitive proxy statement.
2 min readCompass Therapeutics has released its full 2025 financial results, highlighting significant progress in its clinical-stage pipeline. The company reported $209 million in cash and marketable securities, providing a runway into 2028. Key updates include reaching the event threshold for its tovecimig study in biliary tract cancer, expanding cohorts for CTX-8371 in TNBC and NSCLC, and FDA clearance for CTX-10726, with Phase 1 studies commencing.
4 min readCompass Therapeutics' stock (CMPX) has reached a new 52-week high of $6.51 USD, marking a significant surge of 98.76% over the past year. The company, with a market capitalization of $1.14 billion, has seen substantial growth due to strategic advancements and strong investor confidence. Analysts maintain bullish ratings, projecting further upside potential for the biotech firm.
2 min readThe mean of analysts' price targets for Compass Therapeutics, Inc. (CMPX) points to a 154.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
3 min readBOSTON, Nov. 25, 2025 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( NASDAQ:CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the ...
2 min readBOSTON, Nov. 25, 2025 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the ...
2 min readORLA, FIGS and CMPX emerge as breakout candidates as traders scan for stocks nearing or clearing key resistance levels.
4 min readBOSTON, Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( "Compass" ) ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will ...
2 min read
